Yeah, the timeline for sales success has always been considered about 1-YR after FDA approval.
We've spoken about this before and IMO most Bot forum members understand and believe that around June 2025, the price will be above $1.00.
Which in truth is amazing, considering they fluked Sofdra and how they ended up not paying future royalties is nothing more than epic Management chess.
After sales start happening and the cash cow begins to generate, maybe they might re-look at acne or a number of the other pipeline products again. That's Yr-2, I suppose but there's a lot to look forward to in the next few years. If it doesn't get bought out by a big pharmo?
Bot Chart, page-14304
-
- There are more pages in this discussion • 1,516 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
-0.010(3.08%) |
Mkt cap ! $581.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.5¢ | 31.5¢ | $1.126M | 3.508M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 1152626 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 347033 | 6 |
View Market Depth
| Last trade - 15.54pm 06/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |